

|                         |   |
|-------------------------|---|
| 1. Record Nr.           | UNINA9910807741603321   |
| Titolo                  | Advances in medicine and biology [[electronic resource] ] . Volume 6 // Leon V. Berhardt, editor  |
| Pubbl/distr/stampa      | New York, : Nova Biomedical Books, c2010  |
| ISBN                    | 1-61728-045-3   |
| Descrizione fisica      | 1 online resource (296 p.)  |
| Collana                 | Advances in Medicine and Biology ; ; v.6  |
| Altri autori (Persone)  | BerhardtLeon V  |
| Disciplina              | 616   |
| Soggetti                | Medicine<br>Biology   |
| Lingua di pubblicazione | Inglese   |
| Formato                 | Materiale a stampa  |
| Livello bibliografico   | Monografia  |
| Note generali           | Description based upon print version of record.   |
| Nota di bibliografia    | Includes bibliographical references and index.  |
| Nota di contenuto       | <p>""ADVANCES IN MEDICINE AND BIOLOGY VOLUME 6""; ""CONTENTS""; ""PREFACE""; ""ZINC-BASED BIOMATERIALS""; ""BIOLOGICAL ASPECTS OF ZINC""; ""ZINC BIOMATERIALS""; ""ZINC OXYCHLORIDE CEMENTS""; ""ZINC OXIDE EUGENOL CEMENTS""; ""ZINC PHOSPHATE CEMENTS""; ""ZINC POLYCARBOXYLATE CEMENTS""; ""GLASS POLY(ALKENOATE) CEMENTS""; ""GLASSES USED IN GPCS""; ""ACID COMPONENTS USED IN GPCS""; ""THE ROLE OF ADDITIVES TO GPCS""; ""MECHANICAL PROPERTIES OF GPCS""; ""BIOLOGICAL AND ION RELEASE PROPERTIES OF GPCS""; ""ALUMINIUM FREE GPCS""; ""STRUCTURE AND REACTIVITY OF ALUMINIUM FREE IONOMERGLASSES""</p> <p>""STRENGTH OF ALUMINIUM-FREE GPCS""""OPTIMISATION OF RHEOLOGICAL PROPERTIES OF ZN-GPCS""; ""IN VITRO ANALYSIS OF ALUMINIUM-FREE GPCS""; ""IN VIVO ANALYSIS OF ALUMINIUM-FREE GPCS""; ""OTHER ASPECTS OF ALUMINIUM-FREE GPCS""; ""APPLICATIONS FOR ALUMINIUM-FREE GPCS""; ""FUTURE PERSPECTIVES OF ALUMINIUM-FREE GPCS""; ""REFERENCES""; ""THE EFFECTS OF DRUGS ON VERBAL FLUENCY:MECHANISMS OF DRUG RELATED FLUENCY INAPHASIA""; ""ABSTRACT""; ""INTRODUCTION""; ""NEUROANATOMY OF SPEECH AND LANGUAGE""; ""NEUROCHEMICAL BASES OF SPEECH AND LANGUAGE""; ""The Primary Neurotransmitters""</p> <p>""Glutamate, l<sup>3</sup>-Aminobutyric Acid and Glycine""""Neuromodulators and Hormones""; ""Catecholamines""; ""Acetylcholine""; ""Serotonin""; ""DEFINITION OF FLUENCY""; ""NEUROPHARMACOLOGY OF VERBAL</p> |

FLUENCY, SPEECH AND LANGUAGE"; "Agents which Increase Cerebral Perfusion"; "Dopaminergic Agents"; "Amphetamines"; "Serotonin"; "Cholinergic Drugs"; "Piracetam"; "Zolpidem"; "Amantadine"; "Antiepileptic Agents"; "Drugs which have Speech and Language Side Effects"; "CLINICAL CASE"; "CONCLUSION"; "REFERENCES"; "PSORIASIS AS A MULTISYSTEM INFLAMMATORY DISEASE"; "ABSTRACT"

"1. CLINICAL FEATURES OF PSORIASIS"; "2. TREATMENT OPTIONS FOR PSORIASIS"; "3. PATHOGENESIS OF PSORIASIS"; "4. SYSTEMIC MANIFESTATIONS OF INFLAMMATORY DISORDERS"; "5. CLINICAL LINK BETWEEN PSORIASIS AND ATHEROSCLEROSIS"; "6. OPHTHALMIC AND RENAL MANIFESTATIONS OF PSORIASIS"; "7. SIMILARITIES BETWEEN MOLECULAR MECHANISMS OF PSORIASIS AND OTHER INFLAMMATORY DISORDERS"; "8. CAN TREATMENT OF PSORIASIS ALSO IMPROVE ITS SYSTEMIC MANIFESTATION?"; "9. DELINEATING PSORIASIS AS A MULTISYSTEM INFLAMMATORY DISEASE: 5 YEAR VIEW"; "REFERENCES"

"REPACKAGING OF ANTI-GLAUCOMA MEDICINES: NEW THERAPEUTIC VISTAS"; "ABSTRACT"; "INTRODUCTION"; "CHOLINERGIC AGENTS"; "Pilocarpine"; "NON-SELECTIVE ADRENERGIC AGONISTS"; "CARBONIC ANHYDRASE INHIBITORS"; "Acetazolamide"; "Dorzolamide and Brinzolamide"; "1-ADRENERGIC AGONIST"; "BETA-BLOCKING AGENTS"; "Timolol"; "Betaxolol"; "Levobunolol"; "Carteolol"; "PROSTAGLANDIN ANALOGS"; "Unoprostone Isopropylate"; "Latanoprost"; "COMBINATION"; "CONCLUSION"; "REFERENCES"; "THE UTILIZATION OF TECHNOLOGY IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER"; "ABSTRACT"; "INTRODUCTION"

---